Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Drug Discovery Platform Suppliers In Europe
9 companies found
based inGeneva, SWITZERLAND
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric ...
based inVilligen, SWITZERLAND
InterAx combines machine learning, mathematical modeling of cellular processes, and experimental methods derived from more than 10 years of fundamental research to generate high-efficacy leads for a given GPCR target. We decipher drug effects on ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
based inGranada, SPAIN
Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas. Its pharma division is mainly devoted ...
Neuron Biolabs develops biosolutions for application in the pharmaceutical and agri-food industries through its specialised divisions. The Pharma division is dedicated fundamentally to the search for preventative drugs and treatments for ...
based inOttawa, SWITZERLAND
Orion Biotechnology is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. The company is advancing a diversified ...
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the ...
based inOxford, UNITED KINGDOM
Orbit was founded By Professor Terry Rabbitts and Professor Graham Ogg in 2015 as a spin-out from the University of Oxford. The company’s focus is to identify therapeutic peptides using its unique peptide display platform. In 2021 the organisation ...
Orbit presents DNA and peptide on the surface of a microbead. This allows for unbiased libraries and a tunable multivalent display that gives access to huge chemical diversity. Our display technology can deal with unnatural amino acids and ...
based inLeiden, NETHERLANDS
A leading pioneer in leveraging iPSC innovation for drug discovery. The catalyst with the requisite iPSC know-how and experience to empower innovators in drug discovery to advance their science relentlessly, consistently and efficiently. For the ...
based inSchlieren, SWITZERLAND
The biotech-company EraCal Therapeutics Ltd. is a spin-off from the University of Zurich and Harvard University. The company is privately held by a biotech-specialized investor base incl. BERNINA BioInvest, Redalpine, and UZH Life Sciences ...
EraCal’s platform enables unbiased and large-scale in vivo drug discovery in zebrafish larvae. The journal Science Advances published part of EraCal’s translational proof of concept. ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded ...